Structure-activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors

More about Open Access at the Crick

Abstract

The 2-oxoglutarate-dependent hypoxia inducible factor prolyl hydroxylases (PHDs) are targets for treatment of a variety of disease states including anemia. One PHD inhibitor is approved for use in the treatment of renal anemia and others are in late stage clinical trials. However, the number of reported templates for PHD inhibition is limited. We report structure-activity relationship and crystallographic studies on a promising class of 4-hydroxypyrimidine-containing PHD inhibitors.

Journal details

Journal ChemMedChem
Volume 15
Issue number 3
Pages 270-273
Available online
Publication date